Genzyme in the UK

Company Info

Andrew Lansley MP, Shadow Secretary of State for Health, sees cutting edge biotech science at Genzyme Europe Research in Cambridge

Date: July 3, 2009

New Site Head, Peter Harris, Presents Genzyme’s R&D and Clinical Research Capabilities

South Cambridgeshire MP and Shadow Secretary of State for Health Andrew Lansley CBE, welcomes Peter Harris to his new role as Genzyme Europe R+D site head today. On a visit to Genzyme Europe’s Research HQ on the Cambridge science park, the MP for South Cambridgeshire is Mr Harris’ first VIP visitor. During his site tour Mr Lansley will get an in depth briefing on the cutting edge science and clinical programmes carried out at Genzyme’s first dedicated R&D facility in Europe.

Genzyme chose Cambridge as the ideal location for its research HQ in Europe because of its international reputation for the quality of its scientific and medical research. Genzyme’s R&D facility in Cambridge conducts research into advanced treatments for cancer, kidney diseases and immune-mediated diseases and manages a range of clinical trials –including key trials in multiple sclerosis. The Company’s science team is continuing the traditions established in the Cambridge region by being at the forefront of research into human monoclonal antibodies. The Cambridge BMRA (Bio-Medical and Regulatory Affairs) group conduct global clinical trials, obtain regulatory approval for new medicines and perform all regulatory activities, for many countries. Therapeutic areas covered include Biosurgery, Oncology (cancer) and Renal (kidney) medicine.

Mr Lansley MP, said: “I have been very pleased to see some of the ways in which Genzyme are developing new and innovative therapies to benefit patients.  As a local MP and Shadow Health Secretary, it is inspiring to see how the Science for which Cambridge is famous is being developed here, to bring great benefits in treatment for the future.”

Peter Harris, Genzyme Europe’s new R+D site head said; “We were able to share with Andrew Lansley some of the exciting drug developments Genzyme hopes will benefit UK cancer and multiple sclerosis patients in the coming years”

Globally, Genzyme is recognised as one of the leaders in the biopharmaceutical industry. With a mission to improve the lives of patients suffering from life-threatening diseases, the Company is committed to developing and delivering highly effective therapies and diagnostic products. Genzyme in the UK employs approximately 600 people in research, development as well as commercial manufacturing and distribution roles across four different sites in Cambridge, Haverhill, Oxford and Kent.

Paul Drohan, Vice President and General Manager of Genzyme UK & Ireland said; “Genzyme has a long history in the UK, going back to 1981. Since then, our UK operations have grown in size and scope, most recently with the growth of the Haverhill manufacturing facility last year. Even during the current economic situation we continue to expand and create new jobs and opportunities across all our UK sites and to occupy a significant presence in the East of England and the UK’s biotechnology industry.”

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion.

With many established products and services helping patients in approximately 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.

Genzyme in the UK

Genzyme in the UK employs 600 people in research, development as well as commercial manufacturing and distribution roles. Genzyme UK comprises four different sites; Oxford, Kent, Haverhill and Cambridge.

Genzyme Therapeutics operates from the Oxford office and markets products for the treatment of patients with chronically debilitating diseases, like genetic disorders, such as lysosomal storage disorders (LSDs).

Genzyme Diagnostics UK is based on two sites at West Malling and Allington, near to Maidstone in Kent. Genzyme Diagnostics UK includes a Sales and Marketing group, Manufacturing Operations and a Research and Development Team.

Genzyme Haverhill Operations is located on the Cambridgeshire Suffolk border. The site has been a part of Genzyme since 1982, employs 350 people and has three distinct functions: cold chain supply centre, manufactures APIs and scale up and development of Genzyme’s new synthetic molecules.

Genzyme Europe Research is Genzyme’s first dedicated R&D facility in Europe. The science team is currently focused on Antibody Technology.

Highlight

  • Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right

    Sanofi-aventis and Genzyme Corporation announced that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion. Read the full corporate press release.

Contact Info:

Genzyme Therapeutics Ltd
4620 Kingsgate
Cascade Way
Oxford Business Park South
Oxford
OX4 2SU
Tel: +01865 405200
Fax: +01865 774172
Email

Contact Info:

Genzyme Ltd, Haverhill Operations
12 Rookwood Way
Haverhill
Suffolk
CB9 8PU
Tel: +01440 703522
Fax: +01440 716269

'